Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

595391.pdf (125.93 KB)

Document type

Article

Version

Published version

Publication date

2010-03-01

All rights reserved

Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/177207

HDR and LDR brachytherapy in the treatment of lip cancer: the experience of the Catalan Institute of Oncology

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.5114/jcb.2010.13717

Abstract

Purpose: lip cancer can be treated by surgery, external radiotherapy, and/or brachytherapy (BT). In recent years, BT has become increasingly favored for this type of cancer. The aim of the present study was to analyze local control and survival of patients treated at our institution between July 1989 and June 2008. Material and methods: we performed a retrospective study of 121 patients (109 males and 12 females) who underwent lip cancer brachytherapy from July 1989 to June 2008. Median age was 67 years and median follow-up was 31.8 months (range 20-188 months). Out of 121 patients, 100 (82.6%) were treated with low dose rate (LDR) BT while the remaining 21 patients (17.4%) received high dose rate (HDR) BT. Results: the most common cell type was squamous cell carcinoma (115 cases; 95%) and most tumors were located on the lower lip (107 patients; 88.4%). Most cases were either stage T1 (62 patients; 51.2%), or T2 (44 cases; 36.4%). After 15 years of follow-up, overall survival was 89.5%, cause-specific survival 97.8%, and disease-free survival 86.6%. Local, regional, and distant control at 15 years were 90%, 92%, and 98.8%, respectively. Grade 3 mucosal toxicity was observed in 23% of patients treated with LDR compared to 33% of HDR patients, and grade 4 mucosal toxicity in 9% versus 0% in the HDR group. Conclusions: our findings confirm that brachytherapy is an effective treatment for lip cancer. The results from our series are in line with those published elsewhere. Based on our limited data, HDR appears to be equally as good as LDR, although this needs to be confirmed by further studies.

Subject

Braquiteràpia, Càncer de boca, Llavis, Radioteràpia

Subject (English)

Radioisotope brachytherapy, Oral cancer, Lips, Radiotherapy

Citation

Collections

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citation

QUEREJETA AYERRA, Arrate, et al. HDR and LDR brachytherapy in the treatment of lip cancer: the experience of the Catalan Institute of Oncology. Journal of Contemporary Brachytherapy. 2010. Vol. 2, num. 1, pags. 9-13. ISSN 1689-832X. [consulted: 18 of August of 2026]. Available at: https://hdl.handle.net/2445/177207

Export metadata

JSON - METS

Share record